Prosecution Insights
Last updated: November 04, 2026
Application No. 18/747,146

POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS

Non-Final OA §DOUBLEPATENT
Filed
Jun 18, 2024
Priority
Oct 29, 2012 — provisional 61/719,932 +4 more
Examiner
KELLY, ROBERT M
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Molecular Transfer Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
704 granted / 950 resolved
+14.1% vs TC avg
Strong +24% interview lift
Without
With
+24.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
53 currently pending
Career history
988
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
18.9%
-21.1% vs TC avg
§102
16.0%
-24.0% vs TC avg
§112
43.2%
+3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 950 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claims 41-60 are pending as amended 8/27/24 and are considered herein. Formalities: The IDS filing of 9/18/24 and references cited therein have been considered. A signed copy of the IDS is provided herewith. The Drawings of 6/18/24 are accepted. The specification of 6/18/24 is accepted. Applicant’s priority is noted to be: Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 41-60 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 10,155,780. Although the claims at issue are not identical, they are not patentably distinct from each other because: Claim 1: patent Claim 1 teaches: Formula I, or a pharmaceutically acceptable salt thereof; X may be independently selected from a Markush including all presently-claimed embodiments. Y is chosen from (C1-C6)alkyl. R is chosen from a Markush of the same embodiments. R1 may be from a Markush including all presently claimed embodiments. R3 may be from a Markush including all presently claimed embodiments. R11 through R14 are chosen from a Markush of the same embodiments. Claim 42: X may be selected from a Markush from a Markush comprising the same embodiments (e.g., Claim 1); Y may be (C1-C6)Alkyl (e.g., Claim 1); R may be chosen from the same Markush group (e.g., Claim 2); R1 may be (C1-C6)alkyl (e.g., Claim 2) or (CH2)jOR11 (e.g., Claim 1); R3 may be H (e.g., Claim 1) or (CH2)jNR12R13 (e.g., Claim 1); R11 may be from the same Markush (e.g., Claim 2); R12 and R13 may be of the same Markush (e.g., Claim 1). Claim 43: X may be selected from C(O)O and O(O)C (e.g., Claims 1-3). Y may be (C1-C4)alkyl (e.g., Claim 3); R may be of the same Markush (e.g., Claim 3); R1 may be selected from (C1-C6)alkyl (e.g., Claim 3) or (CH2)jOR11 (e.g., Claim 1); R3 may be (CH2)jNR12R13 (e.g., Claim 1); R11 may be hydrogen (e.g., Claim 1) or (C1-C6)alkyl (e.g., Claims 1-3); R12 and R13 may be independently from the same Markush (e.g., Claim 1). Claim 44: X may be chosen independently from a markush including the same embodiments (e.g., Claim 1). Y may be (C1-C4)alkyl (e.g., Claim 2); R may be (C2-C20) alkyl or alkenyl (e.g., Claim 4); R1 may be chosen from a Markush including the same embodiments (e.g., Claim 4); R3 may be chosen from a Markush including the same (e.g., Claims 1 and 4). Claim 45: X may be selected from the same embodiments (e.g., Claim 5); Y may be the same (e.g., Claim 5); R may be at least propyl (e.g., Claim 5); R1 may be at least methyl (e.g., Claim 5); R3 may be the same (CH2)jNR12R13 (e.g. Claim 1); R12 and R13 may be alkyl groups (e.g., Claim 1) where the specification defines such alkyl groups as specifically including straight chain and branched chain saturated hydrocarbons, and minimally, all members with about 1-20 carbons, and provides as part of the definition, all of the present embodiments (e.g., paragraphs 11-12). Thus, as part of the essential written description for the claim terms, the same is specifically disclosed. J may be 0-6 (e.g., Claim 1). Claim 46: e.g., Claim 7, teaches the addition of a neutral lipid. Claim 47: e.g., Claim 7 teaches the addition of a cationic lipid. Claim 48: e.g., Claim 7 teaches the addition of a polyamine transfection agent. Claim 49: e.g., Claim 7 teaches the addition of a fusion agent. Claim 50: e.g., Claim 7 teaches the addition of a cell surface ligand, which may also comprise a polycationic nucleic acid biding moiety. Claim 51: Claim 7 teaches a nuclear localization peptide, which may comprse a polycationic nucleic acid binding moiety (e.g., Claim 16). Claim 52: Claim 7 teaches amphipathic peptides, Claim 7 also teaches several peptides which also act as fusion agents for the same. Claim 53: Claim 7 teaches a nucleic acid. Claim 54: Claim 7 teaches nucleic acids, which are defined as including RNA or DNA (e.g., paragraph 40). Also, Claim 25 teaches RNAi. Claim 55: Claim 7 teaches nucleic acids, which are defined as including RNAi molecules (e.g., paragraph 40). Also, Claim 25 teaches RNAi. Claim 56: Claim 23 teaches method of introducing the same to a eukaryotic cell. Claims 57-58: paragraph 127 teaches, as part of the essential written description, that eukaryotic cells include human and animal cell lines. Claim 59: Claim 24 teaches the same method of expressing a protein by administration of the composition and an expression vector. Claim 60: Claim 25 teaches the inhibition of expression, by administering an RNAi molecule. Thus, in light of the patent, and its essential written description for the claimed subject matter, the invention is obvious. The Artisan would do so and expect success, as it is claimed subject matter. Claims 41-60 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 10,968,240. Although the claims at issue are not identical, they are not patentably distinct from each other because: Claim 41: Claim 1 teaches a compound of the same of the same formula, or a pharmaceutically acceptable salt thereof; X may be chosen from a Markush that includes the same members presently claimed; Y: is chosen from (C1-C6)alkyl; R may be chosen from a Markush of the same members. R1 is chosen from a Markush including the presently claimed embodiments. R3 is chosen from a Markush including the same embodiments presently claimed. R11-R14 are chosen from a Markush of the same embodiments presently claimed. Claim 42: X comprises a Markush of the same members (Claim 1); Y may be (C1-C4)alkyl (e.g., Claim 2); R may be chosen from the same Markush (e.g., Claim 2); R1 may be chosen from (C1-C6) alkyl (e.g., Claim 2) and (CH2)jOR11 (e.g., Claim 1); R3 may be (CH2)jNR12R13 (e.g., Claim 1); R11 may be H or (C1-C6)alkyl (e.g., Claim 2); R12 and R13 may be chosen from the same group (e.g., Claim 1). Claim 42: X may be chosen from a Markush including the same members (e.g., Claims 1- 2); Y may be (C1-C4) alkyl (e.g., Claim 2); R may be chosen from the same Markush groups (e.g., Claim 2); R1 is selected from (C1-C6) alkyl or (CH2)jOR11 (e.g., Claim 3); R11 may be chosen from the same Markush (e.g., Claim 2); R12 and R13 may be many of the same embodiments (e.g., Claim 1). Claim 43: X may be selected from a Markush comprising the same embodiments (e.g., Claims 1-3); Y is (C1-C4)alkyl (e.g., Claim 2); R1 may be (C1-C6)alkyl (e.g., Claim 2); R3 may be (CH2)jNR12R13 (e.g., Claim 1); R11 may be (C1-C6)alkyl (e.g., Claim 2); R12 and R13 may be from a Markush comprising the present members (e.g., Claim 1). Claim 44: X may comprise either of the presently claimed embodiments (e.g., Claims 1-3); Y may be chosen from C1-C6 alkyl (e.g., Claim 1), which the specification specifically defines as including methyl, ethyl, propyl, and n-butyl (e.g., paragraphs 10-11). R may be chosen from a group including the presently claimed embodiments (e.g., Claim 2); R1 may be chosen from C1-C6 alkyl (e.g., Claim 2), which the specification defines as specifically including methyl, ethyl, propyl, and n-butyl (e.g., paragraphs 10-11). R3 may be chosen from a markush including the same embodiments. Claim 45: X may be chosen from a group, including the same embodiments (e.g., Claim 1); Y may be chosen from a group including (C1-C6)alkyl (Claim 1), which the specification defines specifically includes ethyl (e.g., paragraphs 10-11). R may be chosen from alkyl (e.g., Claim 1) which defines the same embodiments claimed in the specification (e.g., paragraphs 10-11). R1 may be selected from alkyl (e.g., Claim 1) which defines the same embodiments claimed in the specification (e.g., paragraphs 10-11). R3: the patent claims the same embodiment in a markush for R3 (e.g., Claim 1). R12 and R13 may be selected from the same embodiments (e.g., Claim 1, reciting alkyl, which the specification specifically defines as including the presently claimed members (e.g., paragraphs 10-11)). Claim 46: Claim 4 teaches a further inclusion of a neutral lipid. Claim 47: Claim 4 teaches a further inclusion of a cationic lipid. Claim 48: Claim 4 teaches the including of a polyamine transfection agent. Claim 49: Claim 8 teaches a further fusion agent. Claim 50: Claim 4 teaches the further inclusion of a cell surface ligand. Claim 51: Claim 4 teaches the further included cell surface ligand and nuclear localization peptides, as well as ligands optionally comprising a polycationic nucleic acid binding moiety. Claim 52: Claim 4 teaches the amphipathic peptides, and examples are provided which provide the activites. Claim 53: Claim 4 includes a nucleic acid(s). Claim 54: Claim 14 teaches DNA and RNA. Claim 55: Claims 18-19 teach RNAi molecules. Claim 56: Claim 15 teaches the same method of introduction into a eukaryotic cell. Claims 57-58: paragraph 127 teaches, as part of the essential written description, that eukaryotic cells include human and animal cell lines. Claim 59: Claim 16 teaches the same method expressing a protein in a cell, with the vector and composition of Claim 1. Claim 60: Claim 18 teaches inhibiting cell expression, by contact with the composition of Claim 1 and an RNAi molecule. Thus, in light of the patent, the invention is obvious. The Artisan would make it, and expect success, as the patent directly claimed and/or provides the same by way essential written description for the claimed subject matter. Claims 41-42 and 46-60 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 12,043,639. Although the claims at issue are not identical, they are not patentably distinct from each other because: Claim 41: patent Claim 1 teaches the same formula I or pharmaceutically acceptable salt thereof. X may be chosen from the Markush in Claim 1; Y may be several members that infringe present Y scope; R may be (C2-C20) alkyl or alkenyl, which the specification defines alkyl embodiments infringing (e.g., paragraphs 10-11) R1 may be several embodiments of alkyl in Claim 1; R3 may be CH2NH2, which infringes (Claim 1); R11-R14 may be hydrogen, which would produce the emobidments of the patent. Claim 42: X may be the same embodiments in Claim 1. Y may be methyl, ethyl, n-propyl, or n-butyl (e.g., Claim 1); R may be C2-C20 alkyl or alkenyl (e.g., Claim 1); R1 may be methyl, ethyl, propyl or butyl, e.g., Claim 1); R3 may be CH2NH2, e.g., Claim 1. Claim 46: Claim 5 teaches neutral lipids. Claim 47: Claim 6 teaches a cationic and a neutral lipid. Claim 48: Claim 7 teaches polyamine transfection reagents. Claim 49: Claim 8 teaches a fusion agent. Claim 50: Claim 9 teaches cell surface ligands and comprising a polycationic nucleic acid binding moiety. Claim 51: Claim 10 teaches nuclear localization peptides and cell surface ligands, optionally comprising a polycationic nucleic acid biding moiety. Claim 52: Claim 11 teaches the amphipathic peptides, optionally covalently linked to polycationic nucleic binding moiety and functioning as a fusion agent. Claim 53: Claim 12 teaches a nucleic acid. Claim 54: Claim 13 teaches DNA and RNA. Claim 55: Claim 14 teaches RNAi. Claim 56: Claim 15 teaches introducing a composition into a eukaryotic cell, comprising the contacting of the same and the composition to a eukaryotic cell. Claim 57: Claim 16 teaches a human cell. Claim 58: Claim 17 teaches animal cell. Claim 59: the same method of expressing a protein in a cell is taught in Claim 18. Claim 60: the same method for inhibiting expression of a protein is taught in Claim 19. Thus, in light of the patent and its essential written description for the claims, the invention is obvious. Such would be done and expected to succeed, as it is claimed subject matter. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT M KELLY whose telephone number is (571)272-0729. The examiner can normally be reached M-F: 8a-5p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571-272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ROBERT M. KELLY Examiner Art Unit 1638 /ROBERT M KELLY/ Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Jun 18, 2024
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758769
Transdermal Optogenetic Peripheral Nerve Stimulation
3y 11m to grant Granted Oct 13, 2026
Patent 12760330
COMPOSITIONS AND METHODS FOR TREATING CEP290 ASSOCIATED DISEASE
3y 8m to grant Granted Oct 13, 2026
Patent 12747425
EX VIVO PROLIFERATION OF EPITHELIAL CELLS
3y 4m to grant Granted Sep 29, 2026
Patent 12747279
CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
3y 7m to grant Granted Sep 29, 2026
Patent 12729223
CHIMERIC RECEPTOR BINDING PROTEINS FOR USE IN BACTERIAL DELIVERY VEHICLES
3y 4m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
98%
With Interview (+24.1%)
2y 10m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 950 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month